Business Wire

MI-PANGEA

24.5.2023 15:31:26 CEST | Business Wire | Press release

Share
Leather Maker Goes for Gold

Pangea commits to becoming the world’s most trusted, sustainable automotive leather supplier, hitting major targets including LWG Gold certification and publication of an inaugural Sustainability Report. The company announces all manufacturing sites are now certified sustainable by the LWG Gold standard. Most recently, the teams were awarded the highest available standard in South Africa and Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230524005545/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Pangea - Automotive Leather (Photo: Business Wire)

Sustainability reporting and auditing has helped Pangea better understand its organization at an even deeper level than standard automotive audits like ISO and IATF.

“This process has helped us better understand who we are and how we operate. It genuinely resonates with the oneness and standardization themes our brand exudes. Proper execution and year-over-year improvement has helped us strengthen our market leadership, guiding the industry to an even stronger image and material market share.” – Roger Pinto, Director of Sustainability & Innovation

The audit preparation for LWG was new for many of Pangea’s business units. Executives and plant managers alike encouraged teams to focus on sustainable reporting initiatives in 2023, especially LWG. The efforts displayed showed determination, unity, and a corporate commitment to sustainable manufacturing, resulting in nothing short of a mass-scale learning experience.

Sustainability is in focus worldwide and across all industries, naturally becoming important for a global automotive materials manufacturer like Pangea. LWG was founded by leather customers who understand how bio-based operations can truly improve the planet, outlining organizational performance. Commitment to sustainability is a customer priority; and an initiative Pangea chose to embrace. Establishing all sites as gold-certified means the supplier commits to a well-rounded sustainable audit and promises continuous improvement.

“The need to report our sustainable goals and progress was driven by our commitment to not only remain competitive, but to lead the industry in trust, service, and passion for natural leather.” – Randy Johnson, President & CEO

The company’s biggest focus for the next two years will be energy management. As one of the most important sections to LWG, it is also tied to lowering scope 1+2 emissions, ISO 50001 certification, and life cycle assessment (LCA) results. Site based solar projects are a priority, with various sites already operational, and plans for further renewable energy in place. Pangea expects to obtain an annualized 2-3% global energy efficiency by 2025, as well as a 16% reduction of freshwater intake.

To check out Pangea’s sustainability report, click here.

About Pangea

Pangea is a global leather supplier to the world’s leading automotive brands, providing sustainable solutions that drive the future of interiors. Headquartered in Rochester Hills, Michigan, Pangea serves its customers on four continents with nearly 3,500 team members. For more information, visit www.pangeamade.com, and follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005545/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye